Central nervous system (CNS) barriers predominantly mediate the immune-privileged status
of the brain, and are also important regulators of neuroimmune communication. It is …

Cases of PML should be evaluated according to predisposing factors, as these subgroups
differ by incidence rate, clinical course, and prognosis. The three most significant groups at …

Objective: Natalizumab is an effective treatment for patients with multiple sclerosis (MS) that
is associated with a risk of progressive multifocal leukoencephalopathy (PML) …

Progressive multifocal leukoencephalopathy (PML) is an uncommon and often fatal
demyelinating disease of human central nervous system, which is caused by reactivation of …

Since it was first described in 1958, progressive multifocal leukoencephalopathy (PML), a
demyelinating disease of the brain caused by the polyomavirus JC (JCV), has evolved …

Neurological manifestations in pandemics frequently cause short and long-term
consequences which are frequently overlooked. Despite advances in the treatment of …

We describe common and less common diseases that can cause magnetic resonance
signal abnormalities of middle cerebellar peduncles (MCP), offering a systematic approach …

Objective: To evaluate the usefulness of the punctate pattern (PP) for the diagnosis and
follow-up of patients with progressive multifocal leukoencephalopathy (PML). Methods: A …

Progressive multifocal leukoencephalopathy (PML) is a rare, but serious, complication
encountered in patients treated with a select number of disease-modifying therapies (DMTs) …

Progressive multifocal leukoencephalopathy is a demyelinating infection of the
immunosuppressed brain, mediated by the gliotropic polyomavirus JCV. JCV replicates in …